SRR1313151
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- INTERFERON_ALPHA_RESPONSE+0.440
- MYC_TARGETS_V1+0.440
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.380
- MTORC1_SIGNALING+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
- SPERMATOGENESIS+0.340
- CHOLESTEROL_HOMEOSTASIS+0.280
- ADIPOGENESIS+0.240
Top 10 suppressed
- TGF_BETA_SIGNALING-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- UV_RESPONSE_DN-0.380
- ESTROGEN_RESPONSE_EARLY-0.310
- ANGIOGENESIS-0.280
- TNFA_SIGNALING_VIA_NFKB-0.270
- COAGULATION-0.260
- KRAS_SIGNALING_UP-0.250
- APOPTOSIS-0.210
- PROTEIN_SECRETION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613729 | — | E | 0.895 |
| 2 | TCGA-A8-A07R-01A-21R-A034-07 | — | E | 0.867 |
| 3 | SRR8518230 | — | E | 0.865 |
| 4 | TCGA-GM-A3XL-01A-11R-A22U-07 | — | E | 0.864 |
| 5 | SRR8518141 | — | E | 0.862 |
| 6 | SRR8518179 | — | E | 0.860 |
| 7 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.849 |
| 8 | MNG358 | — | — | 0.842 |
| 9 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.835 |
| 10 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.070 | Idelalisib | — uncovered |